Skip to main content
. 2023 Dec 23;8(5):1258–1271. doi: 10.1182/bloodadvances.2023011583

Figure 2.

Figure 2.

Validation of the MLC signature in the Japanese cohort. (A) Strategy used to identify and test the MLC score for the 19-miRNA signature. (B) Heat map of miRNA expression by 69 primary samples from the Japanese cohort, along with clinical information for each case. Six clusters were identified by consensus clustering of the 69 samples using 500 miRNAs (the distance method, Pearson). Cases with an MLC score in the third quartile or higher were defined as having a high MLC score. Samples in Cluster 2 had a high MLC score and were labeled as MLC-like (n = 19). (C) The distribution of MLC scores and EFS in the Japanese cohort. (D) Kaplan-Meier survival curves of EFS and OS for BCP-ALL cases with and without an MLC-like signature. P values are based on the log-rank test. (E) Time-dependent receiver-operating characteristic curve analysis and area under the curve (AUC) of the predictive power of MLC score, miR-92b-3p, and miR-1304-3p expression on 2-year EFS and OS in the TARGET and Japanese cohort. FP, false-positive rate; RPM, reads per million; TP, true-positive rate.